ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib, a TKI initially developed to treat chronic myeloid leukemia (CML), inhibits the BCR-ABL tyrosine kinase, a fusion protein constitutively promoting cell proliferation.